http://www.smart-biggar.ca/files/RxIPUpdate_Mar15_SpecialEdition.jpg

AstraZeneca's LOSEC patent valid and infringed by Apotex

by Mark Biernacki

On March 16, 2015, following a 40-day trial in 2014, Justice Barnes of the Federal Court issued a 175-page decision finding certain claims of Canadian Patent No 1,292,693 ("'693 Patent") valid and infringed by Apotex's manufacture, promotion and sale of Apo-Omeprazole capsules in Canada and elsewhere: AstraZeneca Canada Inc et al v Apotex Inc, 2015 FC 322. AstraZeneca was represented by a trial team from Smart & Biggar, comprised of Gunars Gaikis, Nancy Pei, Mark Biernacki, Lynn Ing, Junyi Chen, Urszula Wojtyra and Cameron Weir.

Click to read full article »

Follow @smartbiggar

RANKINGS AND RECOGNITIONS

Smart & Biggar/Fetherstonhaugh chosen by Managing Intellectual Property as "Canadian Specialty IP Firm of the Year"
Read more »

For more information or to request a copy of any decision, pleading or legislation, please contact:

Nancy Pei (Editor)

 

 

 

CASE-LAW BRIEFS BY:
Andrew Mandlsohn

 
Urszula Wojtyra

 
Cameron Weir

 

 

LITIGATION CONTACTS
Gunars Gaikis
Nancy Pei

 
Steven Garland
Mark Biernacki

 
Sheldon Hamilton
Jeremy Want

 
Yoon Kang
Colin Ingram

 

PROSECUTION CONTACTS
Christopher Robinson
Thuy Nguyen

 
Yoon Kang

 
David Schwartz

 
Daphne Lainson

REGULATORY CONTACTS
Nancy Pei

 
Daphne Lainson

 

 

DISCLAIMER

The preceding is intended as a timely update on Canadian intellectual property and regulatory law of interest to the pharmaceutical industry. The contents of this newsletter are informational only and do not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Smart & Biggar/Fetherstonhaugh

Ottawa   /   Toronto   /   Montreal   /   Vancouver  /   Calgary

smart-biggar.ca